Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk.

Drugs & Aging
Suraj RajasimhanJames D Katz

Abstract

The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a membrane-to-nucleus signaling cascade that effects activation of gene transcription. JAK inhibitors have demonstrated effectiveness in autoimmune diseases such as rheumatoid arthritis. An increased risk of infection, mainly varicella-zoster reactivation, with these new agents is of concern. Comorbid conditions, along with pharmacokinetic variations in drug metabolism in the older population, further increase the risk of adverse outcomes. Newly raised concerns for potential adverse effects such as deep vein thrombosis and pulmonary embolism are essential considerations for clinicians. Older patients are at increased risk because of multiple comorbid conditions and pharmacokinetic changes related to drug metabolism and excretion. Both the US FDA and the European Medicines Agency have issued warnings regarding this risk. These warnings highlight individuals aged > 50 years with concomitant cardiovascular risk factors. Furthermore, the FDA released a black box warning for increased thromboembolic risk associated with JAK inhibitors. As the use of these drugs increases, a solid understanding of adverse effects and risks is critical to those t...Continue Reading

References

Apr 24, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K Schmader
Jan 15, 2004·The Lancet Infectious Diseases·Sara L Thomas, Andrew J Hall
Mar 18, 2009·Immunological Reviews·Kamran GhoreschiJohn J O'Shea
May 25, 2011·Archives of Internal Medicine·Seongeun ChoDarrell R Abernethy
Oct 4, 2012·JAMA : the Journal of the American Medical Association·Marie E HolmqvistJohan Askling
Jan 28, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Martin E DowtyChandra Prakash
Jun 20, 2014·Arthritis & Rheumatology·Kevin L WinthropRichard Riese
Sep 26, 2014·Arthritis Research & Therapy·Jason J Lee, Janet E Pope
Jan 28, 2015·Human Vaccines & Immunotherapeutics·Jun CuiRong-Fu Wang
Jan 1, 2014·Clinical Pharmacology in Drug Development·Pankaj GuptaSriram Krishnaswami
Aug 16, 2016·Proceedings of the National Academy of Sciences of the United States of America·Devapregasan MoodleyChristophe Benoist
May 5, 2017·MMWR. Surveillance Summaries : Morbidity and Mortality Weekly Report. Surveillance Summaries·Walter W WilliamsAmy Parker Fiebelkorn
Aug 29, 2017·Arthritis & Rheumatology·Kevin L WinthropEustratios Bananis
Dec 3, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Abril VerdenKeith B Hoffman
Dec 29, 2017·Nature Reviews. Drug Discovery·Daniella M SchwartzJohn J O'Shea
Jul 13, 2018·Journal of Leukocyte Biology·Massimo GadinaJohn J O'Shea
Jan 10, 2019·Nature Reviews. Rheumatology·John J O'Shea, Massimo Gadina
Jan 22, 2019·Arthritis & Rheumatology·Peter C TaylorTsutomu Takeuchi
Feb 27, 2019·Rheumatology·Massimo GadinaJohn J O'Shea

❮ Previous
Next ❯

Citations

Apr 20, 2021·Drugs & Aging·Carlos Antonio MouraCarlos Geraldo Moura
Jun 12, 2021·Zeitschrift für Gerontologie und Geriatrie·Ilke Coskun Benlidayi, Yesim Gokce Kutsal
Jun 14, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Juliana SetyawanMoshe Fridman
Aug 28, 2021·The Journal of Allergy and Clinical Immunology·George E FragoulisStefan Siebert
Nov 2, 2021·Expert Review of Clinical Immunology·Giuseppe IngrasciGil Yosipovitch
Feb 8, 2022·Expert Review of Clinical Immunology·Parker J FunkSteven R Feldman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

© 2022 Meta ULC. All rights reserved